Integrated Protocol for Assessing Meningeal Lymphatics: Cisterna Magna Injection, Lymph Node Imaging, Meningeal Dissection, and Whole-Mount Staining
May 29th, 2026
Here, a protocol is presented to assess mouse meningeal lymphatic vessels (MLVs), which play an important role in multiple neurologic diseases. The goal of this protocol is to provide an integrated method that enables both functional evaluation of tracer drainage and detailed morphological characterization of the dorsal MLVs network.
Our research focuses on mouse meninging lymphatic vessel function and morphology assessments method. This protocol supports neurological disease models, drug delivery, molecular correlation, and the translational studies. To begin, gather the surgical instruments and required buffers.
Use blunt forceps to break off the 30 gauge needle and retain the tip. Using a 30 centimeter length of polyethylene 10 or PE10 tube, connect the broken 30 gauge needle to the microinjection needle containing a 30 gauge needle. Mount the assembled needle and tubing onto the microinjection pump.
Weigh the mouse. After anesthetizing the mouse via intraperitoneal injection, confirm that the toe pinch reflex ceases and respiration becomes slow and steady. Apply dipilatory cream to the cervical region to remove hair over the lymph nodes.
Shave the dorsal neck skin. Place the mouse in a stereotaxic frame on a heating pad. Tilt the head at a 120 degree angle to the trunk.
Clean the area sequentially with povidone iodine and 75%ethanol. Make a midline incision in the skin of the neck. Using two pairs of blunt tipped forceps, separate the muscle layers.
Using fine tipped forceps, dissect through the muscle until the translucent duramater overlying the cisterna magna or CM becomes visible. Retract the muscles to maintain consistent exposure. Under a stereo microscope, use blunt forceps to hold the needle.
Insert the needle at a 45 degree angle to the plane of the duramater to a depth of approximately one to two millimeters. Position the needle bevel parallel to the duramater so that it lies completely beneath it. Use absorbent paper to dry any leaking cerebral spinal fluid or CSF.
Set the microinjection pump to deliver at one microliter per minute. Inject five microliters of ovalbumin, AlexaFluor 647 conjugate solution into the CM, and leave the needle in place for two minutes to prevent backflow. Apply one drop of biological glue onto the meninges and close the surgical incision.
Perform in vivo imaging of the mouse to monitor dye intensity in the cervical lymph nodes or CLN at 30 minutes and 60 minutes. In the IVIS acquisition control panel, select imaging wizard and click next in the pop-up window. Select spectral unmixing/filter scan and click next.
Right click on the probe's name, choose dyes, select AlexaFluor 647, and click next. Select manual settings. Set the exposure time to 0.5 seconds.
And use the mode with an excitation filter at 640 nanometers and an emission filter at 680 nanometers. After decapitating the euthanized mouse, make an incision along the midline of the skull to open the scalp. Using two curved hemostats, separate the scalp bilaterally by gentle retraction.
Insert the curved hemostats into the orbital fossi and strip off the residual scalp from the nasal and oral regions. Remove the mandible while keeping the skull intact. Remove the bone from the base of the skull to expose the ventral aspect of the brain.
Using blunt forceps, carefully extract the brain while avoiding contact with the duramater of the parietal bones. Completely immerse the dorsal skull in five milliliters of 4%paraformaldehyde. Place the sample at four degrees Celsius for 24 hours.
Once the fixed skull reaches the room temperature, wash it with five milliliters of 1XPBS and repeat the wash three times for 10 minutes each. Place the skull dorsal side down in a 10 centimeter dish filled with 1XPBS. Using fine-tipped forceps, grasp or press down on the tympanic bulla, and remove it from the skull.
Employing scissors, trim along the ventral surface of the skull for about two millimeters to smooth it. With forceps, clear residual white tissue from the confluence of sinuses or COS region of the meninges. Using fine micro forceps, gently lift one edge of the meninges from the skull margin.
Lift the opposite edge. Grasp the bowl-shaped rim of the meninges and pull to separate it from the skull in the COS region. Remove the maxillary bone with scissors.
Grasp the rim of the meninges again and pull to separate it from the skull at the frontal bone area. Place the intact meninges into a 24 well plate containing one milliliter of 1XPBS. After blocking and staining the meninges with primary and secondary antibodies, perform imaging.
In vivo imaging revealed distinct oval-shaped fluorescent signals distributed bilaterally in the cervical region following injection. The tracer was clearly visible in the CLNs after injection, with fluorescence intensity peaking at approximately 60 minutes. Fluorescent signals were observed in the isolated superficial and deep cervical lymph nodes.
Failed injections resulted in no detectable fluorescent signal in the cervical region. Immunofluorescent staining for lymphatic vessel endothelial hyaluronin receptor one, or LYVE1, clearly delineated the morphology of lymphatic vessels. A discontinuous LYVE1 signal due to meningeal tearing was observed, compromising reliable quantification.
The absence of the transverse sinus region was visible in compromised samples. Using this approach, researchers can investigate transient function and the dorsal ML-based nasal work morphology in mice. The biggest challenge is performing a current intrasense tendinal injections and the careful meningen dissection while preserving vessel integrity.
Following this procedure, researchers can perform RNA and the protein extraction. Intracranial drug delivery or analysis in disease models.
View the full transcript and gain access to thousands of scientific videos
Overview
This protocol outlines an integrated approach for evaluating meningeal lymphatic vessels (MLVs) in mice, which are crucial for central nervous system (CNS) homeostasis. The method combines intra-cisterna-magna injection of fluorescent tracers, live imaging of cervical lymph nodes (CLNs), meningeal dissection, and whole-mount staining to assess both the morphology and function of MLVs. The procedure is efficient, allowing for comprehensive analysis within approximately three hours.
Key Study Components
Area of Science
- Neuroscience
- Neuroanatomy
- Lymphatic biology
Background
- MLVs are essential for maintaining CNS homeostasis.
- Dysfunction of MLVs is linked to various neurological disorders.
- Detailed assessment of MLVs is necessary to understand their physiological and pathological roles.
- Existing methods often lack integration of functional and morphological analysis.
Purpose of Study
- To provide a comprehensive protocol for evaluating MLVs in mice.
- To enable simultaneous assessment of MLV function and morphology.
- To facilitate studies on CNS physiology and disease mechanisms involving MLVs.
Methods Used
- Intra-cisterna-magna (i.c.m.) injection of fluorescent tracers into the cerebrospinal fluid (CSF).
- Live imaging of tracer drainage to cervical lymph nodes (CLNs).
- Meningeal dissection for tissue preparation.
- Whole-mount staining for detailed morphological analysis of dorsal MLVs.
Main Results
- The protocol enables real-time visualization of tracer movement from CSF to CLNs.
- Allows for detailed morphological assessment of MLVs via whole-mount staining.
- The entire workflow can be completed within 3 hours.
- The method is adaptable for intracranial drug delivery and compatible with molecular analyses (RNA/protein extraction).
Conclusions
- This integrated protocol provides a robust framework for studying MLVs in mice.
- It supports both functional and morphological analyses, enhancing research into CNS homeostasis and disease.
- The approach is versatile and can be adapted for additional experimental applications.
Frequently Asked Questions
Executive Industry Relevance
Integrated assessment of meningeal lymphatic vessels (MLVs) is increasingly vital for de-risking CNS-targeted drug discovery and understanding neurological disease mechanisms. This protocol enables simultaneous functional and morphological evaluation of MLVs, supporting predictive confidence in early-stage CNS research. Its adaptability for molecular analyses and intracranial delivery positions it as a reusable capability across discovery and preclinical workflows.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of MLV function and structure to clarify CNS lymphatic pathways.
- Supports biological de-risking by linking MLV dysfunction to neurological disease models.
- Facilitates predictive confidence in target validation for CNS homeostasis studies.
Screening & Assay Development
- Prepares validated CNS-relevant tissue systems for downstream molecular or imaging assays.
- Standardizes tracer-based functional readouts and whole-mount morphological analysis.
- Enables reproducible, quantitative assessment of lymphatic drainage and vessel integrity.
Translational & Preclinical Research
- Aligns with disease-relevant models by enabling functional and structural biomarker evaluation.
- Supports continuity from discovery through preclinical validation of CNS lymphatic targets.
- Provides mechanistic de-risking for therapeutic hypotheses involving CNS lymphatic dysfunction.
Pipeline & Workflow Integration
This protocol bridges early discovery, target validation, and preclinical research for CNS lymphatic biology, supporting both hypothesis testing and translational biomarker development.
- Discovery Biology: Integrates functional tracer assays and morphological analysis to clarify CNS lymphatic mechanisms.
- Screening: Delivers standardized, quantitative outputs for comparative assessment of MLV function.
- Analytics: Provides real-time imaging and whole-mount data to support statistical comparison of experimental conditions.
- Translational Research: Enables alignment with disease models and supports biomarker continuity across research stages.
- Enterprise Reuse: Adaptable for intracranial delivery and molecular analyses, supporting diverse CNS research pipelines.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in CNS lymphatic research.
- Operational Value: Standardizes procedures for reproducibility and scalability across studies.
- Strategic Value: Informs go/no-go decisions and reduces late-stage biological risk in CNS portfolios.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of CNS-targeted programs.
Implementation Considerations
- Requires expertise in CNS dissection, tracer injection, and live imaging techniques.
- Needs access to infusion pumps, fluorescence imaging systems, and tissue processing infrastructure.
- Demands cross-team standardization for reproducible tracer delivery and imaging protocols.
- Adaptable to fresh or fixed tissues, enabling molecular and morphological analyses.
- Limited to small animal models and dependent on precise surgical and imaging skills.
